Panacea Biotec Q2 FY27 consolidated revenue Rs 189.67 cr, PAT at Rs 11.91 cr
Panacea Biotec’s consolidated revenue from operations rose to Rs 189.67 cr in Q2 FY27, with PAT improving to Rs 11.91 cr from a loss of Rs (14.01) cr a year earlier.
Key takeaways
- Revenue from operations Rs 189.67 cr vs Rs 141.13 cr a year earlier
- Total income Rs 196.27 cr vs Rs 147.53 cr in the corresponding quarter
- Total expenses Rs 182.05 cr vs Rs 169.40 cr in Q2 FY26
- PAT Rs 11.91 cr vs net loss of Rs (14.01) cr a year earlier
- EPS (basic and diluted) Rs 1.90 vs Rs (2.27) in the year-ago quarter
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 189.67 cr | Rs 141.13 cr | +34.4% |
| PAT | Rs 11.91 cr | Rs (14.01) cr | N/A |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 6.28% of revenue, against -9.93% a year earlier.
- Revenue rose 34.4% while total expenses rose 7.5%.
- Cost of materials took 51.3% of revenue, against 33.0% a year earlier.
• Basis: Consolidated statement of financial results, quarter ended September 30, 2026 vs quarter ended September 30, 2025
• Revenue from operations: Rs 189.67 cr (Q2 FY27) vs Rs 141.13 cr (Q2 FY26)
• Other income: Rs 6.60 cr vs Rs 6.40 cr
• Total income: Rs 196.27 cr vs Rs 147.53 cr
• Total expenses: Rs 182.05 cr vs Rs 169.40 cr
• Cost of raw and packing materials consumed: Rs 97.37 cr vs Rs 46.58 cr
• Purchase of traded goods: Rs 1.70 cr vs Rs 1.91 cr
• Changes in inventories of finished goods, traded goods and work-in-progress: Rs (21.02) cr vs Rs 10.45 cr
• Employee benefits expense: Rs 46.21 cr vs Rs 47.71 cr
• Finance costs: Rs 0.60 cr vs Rs 2.14 cr
• Depreciation and amortisation expense: Rs 7.28 cr vs Rs 8.34 cr
• Other expenses: Rs 49.91 cr vs Rs 52.27 cr
• Profit / (loss) before tax and exceptional items: Rs 14.22 cr vs Rs (21.87) cr
• Exceptional items: Rs 2.77 cr vs Rs 2.70 cr
• Profit / (loss) before tax: Rs 16.99 cr vs Rs (19.17) cr
• Total tax expense: Rs 5.08 cr vs Rs (5.16) cr
• PAT (Net profit / (loss) after tax): Rs 11.91 cr vs Rs (14.01) cr
• Total comprehensive income / (loss): Rs 12.29 cr vs Rs (14.02) cr
• Equity share capital: Rs 6.13 cr vs Rs 6.13 cr
• EPS (Basic and Diluted, in Rs): Rs 1.90 vs Rs (2.27)
For the quarter ended September 30, 2026, Panacea Biotec’s consolidated revenue from operations, as reported in the statement of financial results, stood at Rs 189.67 cr, compared with Rs 141.13 cr in the corresponding quarter ended September 30, 2025. Including other income of Rs 6.60 cr (vs Rs 6.40 cr a year earlier), total income rose to Rs 196.27 cr from Rs 147.53 cr.
Total expenses for the quarter were Rs 182.05 cr against Rs 169.40 cr in the year-ago quarter. Within this, cost of raw and packing materials consumed increased to Rs 97.37 cr from Rs 46.58 cr, while purchases of traded goods were Rs 1.70 cr vs Rs 1.91 cr. Changes in inventories of finished goods, traded goods and work-in-progress moved to Rs (21.02) cr from Rs 10.45 cr. Employee benefits expense was Rs 46.21 cr vs Rs 47.71 cr, finance costs were Rs 0.60 cr vs Rs 2.14 cr, and depreciation and amortisation expense was Rs 7.28 cr vs Rs 8.34 cr. Other expenses came in at Rs 49.91 cr compared with Rs 52.27 cr in the same quarter last year.
Profit / (loss) before tax and exceptional items improved to Rs 14.22 cr from a loss of Rs (21.87) cr. After recognising exceptional items of Rs 2.77 cr (vs Rs 2.70 cr), profit / (loss) before tax was Rs 16.99 cr, compared with a loss of Rs (19.17) cr in the corresponding quarter. Total tax expense for the quarter was Rs 5.08 cr against a tax credit of Rs (5.16) cr a year earlier. This resulted in net profit after tax of Rs 11.91 cr, versus a net loss of Rs (14.01) cr in the quarter ended September 30, 2025.
Total comprehensive income for the quarter was Rs 12.29 cr, compared with a total comprehensive loss of Rs (14.02) cr in the year-ago period. Equity share capital remained at Rs 6.13 cr, and basic and diluted earnings per share (annualised, except for quarters and half year) were reported at Rs 1.90, versus Rs (2.27) in the corresponding quarter, as per the statement of financial results.
Track Panacea Biotec Ltd
Cruxal reads every Panacea Biotec Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.